![]() |
Acta Pharmacologica Sinica 2006 January; 27 (1): 100-110; doi: 10.1111/j.1745-7254.2006.00251.x |
| Original Article | [ Full text ] |
| Molecular dynamics simulations of interaction between protein-tyrosine phosphatase 1B and a bidentate inhibitor1 |
Gui-xia LIU2,3,4, Jin-zhi TAN2, Chun-ying NIU2, Jian-hua SHEN2,3, Xiao-min LUO2, Xu SHEN2,3, Kai-xian CHEN2, Hua-liang JIANG2,3,4 2Center for Drug Discovery and Design, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 201203, China; 3School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China |
|
Aim: To investigate the dynamic properties of protein-tyrosine phosphatase (PTP) 1B and reveal the structural factors responsible for the high inhibitory potency and selectivity of the inhibitor SNA for PTP1B.
Methods: We performed molecular dynamics (MD) simulations using a long time-scale for both PTP1B and PTP1B complexed with the inhibitor SNA, the most potent and selective PTP1B inhibitor reported to date. The trajectories were analyzed by using principal component analysis.
Results: Trajectory analyses showed that upon binding the ligand, the flexibility of the entire PTP1B molecule decreases. The most notable change is the movement of the WPD-loop. Our simulation results also indicated that electrostatic interactions contribute more to PTP1B-SNA complex conformation than the van der Waals interactions, and that Lys41, Arg47, and Asp48 play important roles in determining the conformation of the inhibitor SNA and in the potency and selectivity of the inhibitor. Of these, Arg47 contributed most. These results were in agreement with previous experimental results.
|
Keywords: molecular dynamics simulation; principal component analysis; protein-tyrosine phosphatase 1B; type 2 diabetes |
| 1 Project supported by the State Key Program of Basic Research of China (No 2002CB-512802), the National Natural Science Foundation of China (No 20372069, 29725203, and 20072042), a Shanghai Science and Technology Commission Grant No 02DJ14006), the Key Project for New Drug Research from the Chinese Academy of Sciences, and the National High Technology Research and Development Program of China (No 2002AA233061, 2002AA104270, 2002AA233011, and 2003AA235030). This work was also supported by the Foundation of East China University of Science and Technology for Research (No YC0142101). |
|
[ Full text ] |
Copyright©APS 2009 Add: 294 Tai-Yuan Road, Shanghai 200031, China Phn: 86-21-5492-2821 Fax: 86-21-5492-2823 E-mail: aps@mail.shcnc.ac.cn |